Biological
dendritic cell vaccine therapy
dendritic cell vaccine therapy is a biological therapy with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 66.7%.
Total Trials
4
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
1(25%)
Results Posted
0%(0 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_1
2
50%
Ph early_phase_1
1
25%
Ph phase_2
1
25%
Phase Distribution
3
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
1(25.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(2)
Terminated(1)
Detailed Status
Completed2
Active, not recruiting1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
66.7%
Most Advanced
Phase 2
Trials by Phase
Early Phase 11 (25.0%)
Phase 12 (50.0%)
Phase 21 (25.0%)
Trials by Status
active_not_recruiting125%
completed250%
terminated125%
Recent Activity
1 active trials
Showing 4 of 4
active_not_recruitingphase_2
Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies
NCT01697527
completedphase_1
Vaccine Therapy in Treating Patients With Advanced Kidney Cancer
NCT00004880
completedearly_phase_1
Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma
NCT01239875
terminatedphase_1
Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies
NCT02070406
Clinical Trials (4)
Showing 4 of 4 trials
NCT01697527Phase 2
Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies
NCT00004880Phase 1
Vaccine Therapy in Treating Patients With Advanced Kidney Cancer
NCT01239875Early Phase 1
Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma
NCT02070406Phase 1
Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies
All 4 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 4